Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation

Biopharmaceutics and Drug Disposition

Volumn 35, Issue 9, 2014, Pages 543-552

  Lu, Chuang ^a   Suri, Ajit ^a   Shyu, Wen Chyi ^a   Prakash, Shimoga ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

cytochrome P450; drug drug interaction; orteronel; PBPK; renal impairment

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; OMEPRAZOLE; ORTERONEL; PREDNISONE; REPAGLINIDE; THEOPHYLLINE; WARFARIN; ANTINEOPLASTIC AGENT; DRUG; IMIDAZOLE DERIVATIVE; NAPHTHALENE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BINDING; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG SCREENING; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GEOMETRY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MAXIMUM PLASMA CONCENTRATION; MODERATE RENAL IMPAIRMENT; NORMAL HUMAN; PHASE 3 CLINICAL TRIAL; PHYSICAL CHEMISTRY; PHYSIOLOGICAL PROCESS; PLASMA CONCENTRATION-TIME CURVE; SEVERE RENAL IMPAIRMENT; SIMULATION; URINARY EXCRETION; ABSORPTION; BIOLOGICAL MODEL; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; DRUG EFFECTS; DRUG INTERACTION; ENZYME SPECIFICITY; ENZYMOLOGY; KIDNEY FAILURE; LIVER MICROSOME; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; MOLECULAR WEIGHT; PREDICTIVE VALUE;

ABSORPTION, PHYSIOLOGICAL; AGED; ANTINEOPLASTIC AGENTS; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; IMIDAZOLES; METABOLIC CLEARANCE RATE; MICROSOMES, LIVER; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; NAPHTHALENES; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; RENAL INSUFFICIENCY; SUBSTRATE SPECIFICITY;

EID: 84919881867     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.1919     Document Type: Article

References (20)

1. Rowland M, Peck C, Tucker G,. Physiologically-based pharmacokinetics in drug development and regulatory science. Annu Rev Pharmacol Toxicol 2011; 51: 45-73. doi: 10.1146/annurev-pharmtox-010510-100540.
2. Rostami-Hodjegan A, Tamai I, Pang KS,. Physiologically based pharmacokinetic (PBPK) modeling: it is here to stay!. Biopharm Drug Dispos 2012; 33: 47-50. doi: 10.1002/bdd.1776.
3. Zhao P, Rowland M, Huang SM,. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions. Clin Pharmacol Ther 2012; 92: 17-20. doi: 10.1038/clpt.2012.68.
4. Rostami-Hodjegan A, Tucker GT,. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov 2007; 6: 140-148. doi: 10.1038/nrd2173.
5. Ohtsuki S, Schaefer O, Kawakami H, et al., Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. Drug Metab Dispos 2012; 40: 83-92. doi: 10.1124/dmd.111.042259.
6. Achour B, Russell MR, Barber J, Rostami-Hodjegan A,. Simultaneous quantification of the abundance of several cytochrome p450 and uridine 5′-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos 2014; 42: 500-510. doi: 10.1124/dmd.113.055632.
7. Lu C, Miwa GT, Prakash SR, Gan LS, Balani SK,. A novel model for the prediction of drug-drug interactions in humans based on in vitro cytochrome p450 phenotypic data. Drug Metab Dispos 2007; 35: 79-85. doi: 10.1124/dmd.106.011346.
8. Kilford PJ, Stringer R, Sohal B, Houston JB, Galetin A,. Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 2009; 37: 82-89. doi: 10.1124/dmd.108.023853.
9. Zhao P, Zhang L, Grillo JA, et al., Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther 2011; 89: 259-267. doi: 10.1038/clpt.2010.298.
10. Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, Implications for Dosing, and Labeling Recommendations. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf [accessed 31 March 2014 ].
11. Guideline on the Investigation of Drug Interactions. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/07/WC500129606.pdf [accessed 31 March 2014 ].
12. Guidance for Industry. Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. http://www.fda.gov/OHRMS/DOCKETS/98fr/06d-0344-gdl0001.pdf [accessed 31 March 2014 ].
13. Petrylak D, Gandhi JG, Clark WR, et al., A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): updated phase II results. J Clin Oncol 2013; 31 (suppl 6): abstr 59.
14. Dreicer R, Maclean D, Suri A, et al., Phase I/II trial of orteronel (TAK-700)-an investigational 17,20-lyase inhibitor-in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 2014; 20: 1335-1344. doi: 10.1158/1078-0432.CCR-13-2436.
15. Kaku T, Hitaka T, Ojida A, et al.,. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 2011; 19: 6383-6399. doi: 10.1016/j.bmc.2011.08.066.
16. TAXOTERE (docetaxel) injection concentrate [prescribing information]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/020449s059lbl.pdf [accessed 31 March 2104 ].
17. JEVTANA (cabazitaxel) injection [prescribing information]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/201023lbl.pdf [accessed 31 March 2014 ].
18. ZYTIGA (abiraterone acetate) tablets [prescribing information]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/202379lbl.pdf [accessed 31 March 2014 ].
19. XTANDI (enzalutamide) capsules [prescribing information]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/203415lbl.pdf [accessed 31 March 2014 ].
20. Cheng Y, Prusoff WH,. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108.